Tevogen Bio jumps on expanded Microsoft AI collaboration
27/01/2025 11:53
** Shares of drug developer Tevogen Bio TVGN.O rise ~48%
to $2 premarket
** On Friday, TVGN said it is expanding its partnership with
Microsoft MSFT.O to use AI to improve its immunotherapy
treatments
** Co's proprietary tech, PredicTcell, will be developed on
Microsoft's Azure cloud platform to identify precise T-cell
targets - TVGN
** TVGN said it is also using MSFT's AI tools and Azure
cloud platform to proactively investigate potential treatments
for human papillomavirus - viral infection that can cause
genital warts and certain types of cancer
** Last year, TVGN announced its partnership with Microsoft,
and its shares surged to ~54%
** TVGN fell 90.7% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))